上海雪榕生物科技股份有限公司 关于拟变更注册地址、办公地址及修订《公司章程》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 上海雪榕生物科技股份有限公司（以下简称"公司"）于 2026 年 2 月 9 日召 开第六届董事会第四次会议和第六届董事会审计委员会第三次会议，审议通过了 《关于拟变更注册地址、办公地址及修订<公司章程>的议案》。上述议案尚需提 交公司股东会审议。现将相关情况公告如下： 一、变更注册地址、办公地址的情况 证券代码：300511 证券简称：雪榕生物 公告编号：2026-004 公司拟对办公地址进行变更，由"上海市奉贤区汇丰西路1487号"变更为"上 海市青浦区蟠龙路429号中核科创园会议中心C3栋6层"，由此给投资者带来的不 便，敬请谅解。 公司将及时披露本次拟变更注册地址、办公地址事项的相关进展公告。 二、《公司章程》修订情况 根据《公司法》《证券法》《深圳证券交易所创业板股票上市规则》《深圳证 券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等相关法 律法规、规范性文件的规定，结合公司实际情况，公司拟对《公司章 ...

一、召开会议的基本情况 1、股东会届次：2026 年第一次临时股东会 证券代码：300511 证券简称：雪榕生物 公告编号：2026-005 上海雪榕生物科技股份有限公司 关于召开 2026 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 重要提示： 上海雪榕生物科技股份有限公司（以下简称"公司"）第六届董事会第四次 会议审议通过了《关于召开 2026 年第一次临时股东会的议案》，决定于 2026 年 2 月 26 日召开公司 2026 年第一次临时股东会，现将本次股东会的有关事 项通知如下： 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》等法律、行政法规、部门 规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2026 年 02 月 26 日 14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026 年 02 月 26 日 9:1 ...

一、公司不存在《上市公司股权激励管理办法》第七条规定的不得实行股权 激励的下列情形： （一）最近一个会计年度财务会计报告被注册会计师出具否定意见或者无法 表示意见的审计报告； （二）最近一个会计年度财务报告内部控制被注册会计师出具否定意见或者 无法表示意见的审计报告； （三）上市后最近 36 个月内出现过未按法律法规、公司章程、公开承诺进 行利润分配的情形； （四）法律法规规定不得实行股权激励的； 上海雪榕生物科技股份有限公司 董事会薪酬与考核委员会 关于公司 2026 年限制性股票激励计划相关事项的核查意见 上海雪榕生物科技股份有限公司（以下简称"公司"）董事会薪酬与考核委员 会根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股权激 励管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所创业板 上市公司自律监管指南第 1 号——业务办理》和其他有关法律、行政法规、规范 性文件，以及《上海雪榕生物科技股份有限公司章程》（以下简称"《公司章程》"） 等有关规定，对《上海雪榕生物科技股份有限公司 2026 年限制性股票激励计划 （草案）》（以下简称"本次激励计划"）进行了核查，发表核查意见 ...

证券代码：300511 证券简称：雪榕生物 公告编号：2026-003 上海雪榕生物科技股份有限公司 第六届董事会第四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1.本次董事会由董事长蒋智先生召集，会议通知于 2026 年 2 月 4 日以电子 邮件等通讯方式发出。 本议案已经公司审计委员会发表了同意的核查意见。具体内容详见公司公布 在中国证监会指定创业板信息披露网站巨潮资讯网的《关于拟变更注册地址、办 公地址及修订<公司章程>的公告》（公告编号：2026-004）及修订后的《公司章 程》。 本议案以 7 票同意，0 票反对，0 票弃权获得通过。 2.本次董事会于 2026 年 2 月 9 日在上海雪榕生物科技股份有限公司（以下 简称"公司"）会议室召开，采取现场和通讯相结合的方式进行表决。 3.本次会议应出席董事 7 人，实际出席董事 7 人。 4.本次董事会由董事长蒋智先生主持，公司高级管理人员列席了本次董事 会。 5.本次董事会会议的召集、召开和表决程序符合《公司法》等法律、法规及 《公司章程》的有关规定，合法 ...

格隆汇2月10日丨雪榕生物(300511.SZ)公布2026年限制性股票激励计划，本激励计划拟向激励对象授予 的限制性股票数量为2,704.00万股，约占本激励计划草案公告日公司股本总额的4.22%，无预留权益。 本激励计划授予的激励对象总人数为76人，本激励计划授予限制性股票的授予价格为6.26元/股。 ...

证券代码：300511 证券简称：雪榕生物 公告编号：2026-002 上海雪榕生物科技股份有限公司 关于2025年度担保额度预计的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、担保情况概述 上海雪榕生物科技股份有限公司（以下简称"公司"）于2025年4月25日召开了第 五届董事会第二十五次会议和第五届监事会第十五次会议，于2025年5月23日召开了 2024年年度股东大会，分别审议通过了《关于2025年度担保额度预计的议案》。为 满足公司及子公司生产经营和业务发展需要，确保资金流畅通，公司在保证规范运 营和风险可控的前提下，预计在2025年度为子公司向银行或其他金融机构申请融资 业务时提供总额度不超过人民币20.9亿元（含本数）的担保，其中，公司为资产负债 率低于70%的子公司提供担保额度为8.9亿元人民币（含本数），为资产负债率高于 70%的子公司提供担保额度为12亿元人民币（含本数），担保额度有效期限自公司 2024年年度股东大会审议通过之日起至2025年年度股东大会召开之日止，上述担保 额度在有效期限内可以循环使用。具体内容详见公司公布 ...

Market Overview - The planting industry sector increased by 0.28% compared to the previous trading day, with Xue Rong Biological leading the gains [1] - The Shanghai Composite Index closed at 4102.2, up by 0.85%, while the Shenzhen Component Index closed at 14156.27, up by 0.21% [1] Top Gainers in Planting Sector - Xue Rong Biological (300511) closed at 6.27, up by 4.85% with a trading volume of 387,000 shares and a transaction value of 240 million [1] - Nongfa Seed Industry (600313) closed at 8.25, up by 4.04% with a trading volume of 2.6166 million shares and a transaction value of 2.121 billion [1] - Nuo Puxin (002215) closed at 11.49, up by 3.42% with a trading volume of 272,400 shares and a transaction value of 310 million [1] Top Losers in Planting Sector - Dunhuang He V (600354) closed at 7.15, down by 2.59% with a trading volume of 1.1124 million shares and a transaction value of 799 million [2] - Qiu Le Seed Industry (920087) closed at 19.82, down by 2.36% with a trading volume of 256,800 shares and a transaction value of 530 million [2] - Wanxiang Denong (600371) closed at 9.45, down by 1.97% with a trading volume of 346,300 shares and a transaction value of 329 million [2] Capital Flow Analysis - The planting industry sector experienced a net outflow of 709 million from main funds, while retail funds saw a net inflow of 504 million [2] - The main funds showed a net inflow in Xue Rong Biological of 36.2962 million, while retail funds had a net outflow of 14.1443 million [3] - Nuo Puxin had a net inflow from main funds of 29.0745 million, with retail funds also experiencing a net outflow of 789,280 [3]

Summary of the Conference Call Transcript Industry Overview - **Industry Focus**: Edible Mushroom Industry and Cordyceps Sinensis (冬虫夏草) - **Market Growth**: The edible mushroom industry is experiencing a continuous growth trend, with a projected compound annual growth rate (CAGR) of 6.0% from 2019 to 2024 according to the China Edible Mushroom Association [1] Key Insights on Cordyceps Sinensis - **Demand and Supply Dynamics**: There is a sustained increase in demand for Cordyceps Sinensis, with product forms becoming more diverse. Conversely, the supply of wild Cordyceps is declining, while large-scale artificial cultivation is advancing. This may lead to long-term price increases or strong fluctuations [1] - **Policy Support**: Government policies are encouraging the research and cultivation of endangered medicinal materials and the development of substitutes. Continuous technological advancements in artificial cultivation are being made [1] - **Company Initiatives**: Several companies are strategically positioning themselves in the market. For instance, Dongyangguang has an annual production capacity exceeding 60 tons, while Zhongxing Junye is developing factory-based cultivation projects, showing positive profit trends. Xue Rong Biological is accumulating technology for artificial cultivation of Cordyceps Sinensis [1] Insights on the Edible Mushroom Industry - **Market Structure**: The industry is optimizing its market structure, with production capacity returning to rational levels. Leading companies like Zhongxing Junye maintain over 40% market share and a gross margin exceeding 30% [5] - **Price Stabilization**: Prices for various mushroom types, including Enoki mushrooms and Pleurotus eryngii, are stabilizing at the bottom due to supply adjustments by leading companies like Xue Rong Biological and Zhongxing Junye, which are reducing production capacity to alleviate supply pressure [2][3][7] - **Profitability**: The profitability of the double mushroom segment remains stable, supported by sufficient supply and demand driven by the restaurant sector [6][3] Investment Recommendations - **Edible Mushroom Sector**: As companies reduce capital expenditures and production capacity, supply pressure is expected to ease, leading to potential price stabilization and upward movement. Leading enterprises are positioned to improve profitability due to their advantages in scale, technology, and management [8] - **Cordyceps Sinensis Sector**: With rising health awareness, improving policies, and mature artificial cultivation technologies, the artificial cultivation of Cordyceps Sinensis is entering a phase of large-scale industrial development. Companies with forward-looking capacity and technological layouts are expected to show greater growth potential [8] - **Key Companies**: Zhongxing Junye and Xue Rong Biological are highlighted as significant players in the industry [8] Risk Factors - **Market Competition**: Increased competition in the market poses a risk [9] - **Food Safety**: Potential food safety risks could impact the industry [9] - **Innovation Risks**: Risks associated with research and development not meeting expectations [9] - **Raw Material Costs**: Rising costs of raw materials present a financial risk [9]

Investment Rating - The report assigns an investment rating of "Positive" for the industry, marking it as the first rating issued [2]. Core Insights - The edible fungus industry is experiencing growth, with a projected compound annual growth rate (CAGR) of 6.0% for the national edible fungus output value from 2019 to 2024. The market structure is optimizing as production capacity returns to rational levels [5][6]. - The demand for Cordyceps sinensis is increasing due to its various health benefits, and the supply is becoming scarcer due to overharvesting and climate change. This is expected to lead to long-term price increases or strong fluctuations [5][6]. - The report highlights the ongoing technological advancements and policy improvements that are creating new opportunities for the artificial cultivation of Cordyceps sinensis, which is transitioning into a rapid industrialization phase [5][6]. Summary by Sections 1. Cordyceps Sinensis: Continuous Advancement in Large-Scale Artificial Cultivation - The industry chain for Cordyceps sinensis is continuously improving, with applications expanding across pharmaceuticals, health products, and cosmetics [5][9]. - The price of wild Cordyceps sinensis is expected to remain strong due to its increasing scarcity, with prices returning to 210,000-220,000 yuan per kilogram in 2023 [5][28]. - Policies are being implemented to ensure sustainable harvesting and scientific protection of Cordyceps sinensis, promoting the development of artificial cultivation [5][30]. 2. Edible Fungi: Market Structure Optimization and Rational Return of Production Capacity - The edible fungus industry is witnessing stable growth, with the production of enoki mushrooms stabilizing at over 5,300 tons per day in 2023, and the price is expected to recover from its bottom [5][6]. - The production of button mushrooms is stable, with a daily output of 867 tons in 2023, and leading companies maintain a high market share [5][6]. - The demand for king oyster mushrooms is also improving, supported by household consumption and high-end dining, with industrial production reaching 349 tons per day in 2023 [5][6]. 3. Investment Recommendations - The report suggests that the edible fungus industry will see price stabilization and upward movement due to reduced supply pressure from capital expenditure and capacity cuts by enterprises [5][6]. - In the Cordyceps sinensis sector, companies with advanced capacity and technological layouts are expected to show greater growth potential as health awareness increases [5][6].

证券日报网讯1月26日，雪榕生物（300511）在互动平台回答投资者提问时表示，《上市公司证券发行 注册管理办法(2025年修正)》第九条和第十三条中对交易所主板上市公司有相关规定，公司为深交所创 业板上市公司。关于定增，公司将按照规定和要求及时履行信息披露义务。 ...